Cargando…

A Phase III, Double-Blind, Placebo-Controlled, Flexible-Dose Study of Levomilnacipran Extended-Release in Patients With Major Depressive Disorder

Levomilnacipran (1S, 2R-milnacipran) is a potent and selective serotonin and norepinephrine reuptake inhibitor; an extended-release (ER) formulation allows for once-daily dosing. This phase III study (NCT01034462) evaluated the efficacy, the safety, and the tolerability of 40 to 120 mg/d of levomiln...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sambunaris, Angelo, Bose, Anjana, Gommoll, Carl P., Chen, Changzheng, Greenberg, William M., Sheehan, David V.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Williams And Wilkins 2014
Materias:	Original Contributions
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4047313/ https://www.ncbi.nlm.nih.gov/pubmed/24172209 http://dx.doi.org/10.1097/JCP.0000000000000060

Ejemplares similares

Efficacy of levomilnacipran extended-release in improving functional impairment associated with major depressive disorder: pooled analyses of five double-blind, placebo-controlled trials
por: Sambunaris, Angelo, et al.
Publicado: (2014)

Effects of levomilnacipran extended-release on motivation/energy and functioning in adults with major depressive disorder
por: Thase, Michael E., et al.
Publicado: (2016)

Effects of levomilnacipran extended-release on major depressive disorder patients with cognitive impairments: post-hoc analysis of a phase III study
por: Wesnes, Keith A., et al.
Publicado: (2017)

Efficacy of levomilnacipran extended-release in major depressive disorder: pooled analysis of 5 double-blind, placebo-controlled trials
por: Montgomery, Stuart A., et al.
Publicado: (2014)

A randomized, double-blind, placebo-controlled study of flexible doses of levomilnacipran ER (40–120 mg/day) in patients with major depressive disorder
por: Gommoll, Carl P., et al.
Publicado: (2014)

Effects of levomilnacipran ER on fatigue symptoms associated with major depressive disorder
por: Freeman, Marlene P., et al.
Publicado: (2016)

The efficacy of extended-release levomilnacipran in moderate to severe major depressive disorder: secondary and post-hoc analyses from a randomized, double-blind, placebo-controlled study
por: Montgomery, Stuart A., et al.
Publicado: (2014)

Safety and Tolerability of Levomilnacipran ER in Major Depressive Disorder: Results from an Open-Label, 48-Week Extension Study
por: Mago, Rajnish, et al.
Publicado: (2013)

Erratum to: Safety and Tolerability of Levomilnacipran ER in Major Depressive Disorder: Results from an Open-Label, 48-Week Extension Study
por: Mago, Rajnish, et al.
Publicado: (2013)

Vilazodone in patients with generalized anxiety disorder: a double-blind, randomized, placebo-controlled, flexible-dose study
por: Gommoll, Carl, et al.
Publicado: (2015)

Effect of renal impairment on the pharmacokinetics of levomilnacipran following a single oral dose of levomilnacipran extended-release capsule in humans
por: Chen, Laishun, et al.
Publicado: (2015)

Relapse prevention with levomilnacipran ER in adults with major depressive disorder: A multicenter, randomized, double‐blind, placebo‐controlled study
por: Durgam, Suresh, et al.
Publicado: (2019)

Efficacy and safety of multiple doses of levomilnacipran extended-release for the treatment of major depressive disorder
por: Huang, Qunlian, et al.
Publicado: (2016)

Relapse prevention in adults with major depressive disorder treated with vilazodone: a randomized, double-blind, placebo-controlled trial
por: Durgam, Suresh, et al.
Publicado: (2018)

Levomilnacipran for the treatment of major depressive disorder: a review
por: Asnis, Gregory M, et al.
Publicado: (2015)

Effects of vilazodone on suicidal ideation and behavior in adults with major depressive disorder or generalized anxiety disorder: post-hoc analysis of randomized, double-blind, placebo-controlled trials
por: Thase, Michael E., et al.
Publicado: (2017)

The Role of Levomilnacipran in the Management of Major Depressive Disorder: A Comprehensive Review
por: Bruno, Antonio, et al.
Publicado: (2016)

Categorical improvements in disease severity in patients with major depressive disorder treated with vilazodone: post hoc analysis of four randomized, placebo-controlled trials
por: Durgam, Suresh, et al.
Publicado: (2016)

A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, FIXED-DOSE PHASE III STUDY OF VILAZODONE IN PATIENTS WITH GENERALIZED ANXIETY DISORDER
por: Gommoll, Carl, et al.
Publicado: (2015)

Effects of vilazodone on sexual functioning in healthy adults: results from a randomized, double-blind, placebo-controlled, and active-controlled study
por: Clayton, Anita H., et al.
Publicado: (2017)

Efficacy and safety of vilazodone 20 and 40 mg in major depressive disorder: a randomized, double-blind, placebo-controlled trial
por: Mathews, Maju, et al.
Publicado: (2015)

A Phase 3, Placebo-Controlled Trial of Once-Daily Viloxazine Extended-Release Capsules in Adolescents With Attention-Deficit/Hyperactivity Disorder
por: Nasser, Azmi, et al.
Publicado: (2021)

Vilazodone efficacy in subgroups of patients with major depressive disorder: a post-hoc analysis of four randomized, double-blind, placebo-controlled trials
por: Kornstein, Susan, et al.
Publicado: (2018)

Kratom and Pain Tolerance: A Randomized, Placebo-Controlled, Double-Blind Study
por: Vicknasingam, Balasingam, et al.
Publicado: (2020)

Effects of Omeprazole on Sleep Disturbance: Randomized Multicenter Double-Blind Placebo-Controlled Trial
por: Aimi, Masahito, et al.
Publicado: (2014)

Efficacy, Safety, and Tolerability of Centanafadine Sustained-Release Tablets in Adults With Attention-Deficit/Hyperactivity Disorder: Results of 2 Phase 3, Randomized, Double-blind, Multicenter, Placebo-Controlled Trials
por: Adler, Lenard A., et al.
Publicado: (2022)

Pharmacokinetics of Coadministered Viloxazine Extended-Release (SPN-812) and Lisdexamfetamine in Healthy Adults
por: Faison, Shamia L., et al.
Publicado: (2021)

Characterization of Extended-Release Lorazepam: Pharmacokinetic Results Across Phase 1 Clinical Studies
por: Mathew, Sanjay J., et al.
Publicado: (2023)

Cerebrolysin and Recovery After Stroke (CARS): A Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial
por: Muresanu, Dafin F., et al.
Publicado: (2016)

A comparison of the extended-release and standard-release formulations of tacrolimus in de novo kidney transplant recipients: a 12-month outcome study
por: Fanous, Helen, et al.
Publicado: (2013)

Model-Based Approach for Establishing the Predicted Clinical Response of a Delayed-Release and Extended-Release Methylphenidate for the Treatment of Attention-Deficit/Hyperactivity Disorder
por: Gomeni, Roberto, et al.
Publicado: (2020)

Blind Man’s Buff
por: Blackham, George E.
Publicado: (1882)

Monthly Extended-Release Risperidone (RBP-7000) in the Treatment of Schizophrenia: Results From the Phase 3 Program
por: Andorn, Anne, et al.
Publicado: (2019)

MIDAS (Modafinil in Debilitating Fatigue After Stroke): A Randomized, Double-Blind, Placebo-Controlled, Cross-Over Trial
por: Bivard, Andrew, et al.
Publicado: (2017)

Disposition and metabolism of [(14)C]-levomilnacipran, a serotonin and norepinephrine reuptake inhibitor, in humans, monkeys, and rats
por: Brunner, Valérie, et al.
Publicado: (2015)

The role of new antidepressants in clinical practice in Canada: a brief review of vortioxetine, levomilnacipran ER, and vilazodone
por: McIntyre, Roger S
Publicado: (2017)

Sexual dysfunction during treatment of major depressive disorder with vilazodone, citalopram, or placebo: results from a phase IV clinical trial
por: Clayton, Anita H., et al.
Publicado: (2015)

Randomized Controlled Crossover Trials of the Pharmacokinetics of PRC-063, a Novel Multilayer Extended-Release Formulation of Methylphenidate, in Healthy Adults
por: Katzman, Martin A., et al.
Publicado: (2020)

Randomized, Double-Blind, Placebo-Controlled, Flexible-Dose Titration Study of Methylphenidate Hydrochloride Extended-Release Capsules (Aptensio XR) in Preschool Children with Attention-Deficit/Hyperactivity Disorder
por: Childress, Ann C., et al.
Publicado: (2020)

Efficacy and safety of a natural mineral water rich in magnesium and sulphate for bowel function: a double-blind, randomized, placebo-controlled study
por: Bothe, Gordana, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_pka1qhnlr3kerp8vpvhfqsnins